Q4 19 was largely in line as the pick-up in sales in microbiology, driven by equipments, made up for the slowdown in FilmArray, due to rising competition. However, the guidance for FY20 signals a sales deceleration with China, held back by the Coronavirus being the main drag. Lower sales could also affect profitability in FY20. While bioMerieux plans to introduce a test to detect Coronavirus by Q2 20, it is still behind rival Qiagen in terms of test development.
27 Feb 2020
In line Q4 19, overshadowed by cautious outlook for FY20
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In line Q4 19, overshadowed by cautious outlook for FY20
Q4 19 was largely in line as the pick-up in sales in microbiology, driven by equipments, made up for the slowdown in FilmArray, due to rising competition. However, the guidance for FY20 signals a sales deceleration with China, held back by the Coronavirus being the main drag. Lower sales could also affect profitability in FY20. While bioMerieux plans to introduce a test to detect Coronavirus by Q2 20, it is still behind rival Qiagen in terms of test development.